Medical technology company Admedus has attracted investment group Partners for Growth for a $10 million debt facility, as it continues development of its products.
Admedus has appointed current non-executive director, John Seaberg, as non-executive chair. Wayne Paterson has stepped down as chair, and will focus on his role as chief executive officer.
Half of the top twelve trending companies in Techboard's ranking this fortnight are health-techs, with Perth continuing to assert its credentials in the space.
Lee Rodne has resigned as managing director and chief executive officer of Admedus, effective 30 June 2016. Mr Rodne has been a part of the company since the past 10 years.
Fortescue Metals Group is home to two of Western Australia's wealthiest company directors, or so it was believed until a surprise disclosure last month.
Former Fortescue Metals Group chief financial officer and director Chris Catlow has joined Subiaco-based Triton Minerals as its new chairman, with Alan Jenks stepping down from the head of the board to take on a director role today.
Biotech company Admedus has initiated a capital raising comprising a placement and rights issue, with the hope of generating up to $28 million to fund ongoing development of various health care programs.
FEATURE: Biotech and IT companies are enjoying renewed investor interest, but these innovative businesses are facing a changing capital raising market featuring less government support and, in Perth, a drastic shift in the venture capital sector.
Biotech company Admedus has completed an oversubscribed $8 million share placement as it looks to push marketing for its CardioCel regenerative tissue product in Europe and the US.
The Waterberg Coal Company was Western Australia's best-performed listed entity in 2013, providing a whopping 38,748 per cent return to shareholders, according to BNIQ data.
A fourth consecutive month of growth in the market capitalisation of Western Australia's top 100 listed companies is a sign of renewed business confidence within the WA economy, according to market analysts.
Healthcare technology company Allied Healthcare Group will seek to raise $10 million as it looks to launch its CardioCel regenerative tissue patch in Europe.
